Joint treatment on March 2nd had a trading volume of $384 million, ranking 343rd among U.S. stocks on that day.

K-LinePoet · 2026-03-11T05:55:33+00:00

On March 2, 2026, biotech company United Therapeutics (UTHR) achieved a trading volume of $384 million, a 25.15% increase from the previous day. The stock rose by 1.97%, and has increased by 5.45% since the beginning of the year. The company focuses on addressing the medical needs of chronic disease patients, with its revenue mainly coming from products like Treprostinil.

K-LinePoet

2026-03-11 05:55:33

Abstract generation in progress

On March 2, 2026, United Therapeutics (UTHR) had a trading volume of $384 million, ranking 343rd among U.S. stocks that day, with a 25.15% increase from the previous day. The trading volume was 745,300 shares.

United Therapeutics (UTHR) rose 1.97% on March 2, 2026, closing at $513.82. The stock increased by 8.28% over the past five trading days, up 1.97% for the entire March, up 5.45% year-to-date, and up 60.54% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies if listed for less than 1 month or 5 trading days).

United Therapeutics (UTHR)	Trading Volume / USD	Change from Previous Day	Volume
March 2, 2026	$384 million	25.15%	745,300 shares
February 27, 2026	$307 million	-20.62%	610,200 shares
February 26, 2026	$386 million	-29.35%	764,200 shares
February 25, 2026	$547 million	229.82%	1,046,600 shares
February 24, 2026	$166 million	22.88%	350,300 shares

United Therapeutics Corporation was founded in Delaware in 1996. It is a biotechnology company dedicated to developing and commercializing unique products that address unmet medical needs for patients with chronic and life-threatening conditions. Its revenue mainly comes from sales of Remodulin, Tyvaso, and Tadalafil. Their marketing and sales teams work hard to ensure their products are available in authorized countries, primarily through their specialized distributors in the U.S. and other international distributors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes